Our Mission

 

Ninox Medical is a start-up company dedicated to developing disruptive solutions for the treatment of Obstructive Sleep Apnea (OSA).

 

The company is developing a wearable device called the keePAP™, which is based on a novel, proprietary concept for the treatment of OSA. The keePAP™ device is comprised of a lightweight, unobtrusive nasal interface and a miniature battery-operated control unit that make it convenient for use both at home and while traveling.

 

The keePAP™ device is expected to offer a new level of comfort and ease of use, resulting in a remarkable improvement in compliance and becoming the product of choice for the millions who suffer from OSA.

 

 

 

Board Of Directors

 

    David Israeli is a life sciences Partner at Pitango Venture Capital, having joined the firm in 2010. He focuses on companies dealing with medical devices and biopharmaceuticals. Before joining Pitango, David was the Director of Business Development and Marketing at Medtronic Ventor Technologies, following Medtronic’s acquisition of Ventor Technologies in early 2009. Prior to this, David spent several years in the United States. After earning an MBA, he joined Medtronic, Inc. and filled roles ranging from corporate development and M&A to business and market development. David then went on to become the VP of Medical Affairs at Rhythmia Medical (acquired by Boston Scientific in October 2012). David holds an MD from the Hebrew University of Jerusalem and an MBA from the Harvard Business School.  

            David Israeli, MD

                                                                  Partner, Pitango

 

   Valérie Calenda began her career as research scientist in hematology and virology at theInstitut National de la Recherche Médicale (INSERM). After collaborating at a French/USresearch program on HIV at Davis University in California, she joined Transgene, an affiliateof Institut Mérieux focusing on immunotherapy, in 1994 where she was in charge of severalprojects focusing on HIV and Cardiovascular areas until 2000. She then led a spin-off project incardio-vascular therapeutic area before collaborating with a Paris based seed Venture Capitalfirm. Valérie also managed several biotech clinical-stage product developments within theinfectious diseases and oncology disease areas, from pre-IND to Phase 2. This led her to manage both in-licensing and out-licensing activities, including global license agreement and alliance management with Hoffman La Roche, acquisition of biotech assets in Europe and in the US. Valérie joined Merieux Développement as a Partner in January 2010.Valérie received her PhD in Pharmacology from the University of Marseille and . She holds a degree in Hematology and a B.Sc. in Biochemistry-Immunology from the University of Marseille.

            Valérie Calenda, PhD

                                                                  Partner, Merieux Développement

 

   Alex is serial entrepreneur with 28 years of senior management and consultingexperience specializing in product development, business development and marketing and sales in the area of medical devices. Prior to founding Ninox Medical, Alex was an independent consultant specializing in interim executive management and business development services to medical device companies. Alex served as CEO of Motorika - an Israel and U.S. based manufacturer of medical robotics equipment for rehabilitation of stroke patients. Earlier in his carrier Alex founded and was a CEO of Myriad Ultrasound system - an Israel and U.S developer and manufacturer of ultrasound equipment for diagnosis of osteoporosis. Alex started his carrier in 1987 as a development engineer and product manager at Mennen Medical. Alex holds a B.Sc. in Electrical and Computers Engineering from the Ben-Gurion University, Beer-Sheva.

            Alex Rapoport

                                                                  Founder and CEO, Ninox

 

   Dr. Daphne Haim-Langford has over 14 years of managerial experience. Daphnehas been involved in medical device entrepreneurship and specializes in fundraising,strategic planning, marketing, distribution, reimbursement, and product managementin the medical device industry. Prior to joining Xenia, Dr. Haim-Langford was VP Business Development & Marketing at Medingo, an insulin patch pump company which was acquired by Roche. Prior to that, she was General Manager with Per Assist, a Misgav Technology Center portfolio company. Before joining PerAssist, Dr. Haim-Langford was Product Manager for Carmel Biosensor, developing biosensors for glucose and anesthesia. Dr. Haim-Langford is the Chairperson of the Israeli Biomimicry Organization, a nonprofit organization promoting sustainable innovation inspired by nature. She is also a lecturer at the Interdisciplinary Center (IDC) Herzliya Business School. Dr. Haim-Langford holds a Ph.D degree in Biotechnology from Technion and a B.Sc. in Nutrition from Hebrew University (Cum Laude)

           Daphne Haim-Langford, PhD,

                                                                VP Business Dev, Xenia Ventures

© Copyright 2015 Ninox Medical, Inc. All rights reserved.

 

The keePAP™ is an investigational device and is limited by U.S. law to investigational use. This product is not currently available for sale or distribution and has not been approved by the U.S. FDA or by any other country’s regulatory authority.

 

//site by: Pixelfuse.net